IceCure Showcases ProSense® Cryoablation and Sponsors Hands-On Courses at SBI 2025 Symposium

IceCure Medical Ltd. (Nasdaq: ICCM), the company behind the minimally invasive ProSense® cryoablation system, announced its successful participation in the Society of Breast Imaging (SBI) 2025 Breast Imaging Symposium, held April 24–27 in Colorado Springs, Colorado.

IceCure sponsored two breast cryoablation training courses conducted by the SBI on April 24 and 26. Both sessions — which offered hands-on experience with the ProSense® system — were completely sold out. The high turnout reflects a growing interest among radiologists to integrate cryoablation into their clinical practices and highlights the increasing adoption of ProSense® as medical societies expand their education around this minimally invasive technology.

In addition to its sponsorship, IceCure hosted a VIP Exhibitor Hour featuring Dr. Robert C. Ward, a recognized expert in women’s imaging and cryoablation techniques. Dr. Ward, who holds multiple leadership roles at the Warren Alpert Medical School of Brown University and Women & Infants Hospital, led discussions on the rationale and clinical approach behind breast cryoablation. He also shared insights from his published work using ProSense®, including a notable article in the American Journal of Roentgenology titled “Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials.”

IceCure CEO Eyal Shamir commented on the strong alignment between the company’s mission and the SBI’s focus on early detection and intervention. “Once diagnosed by radiologists, ProSense® can quickly and minimally invasively destroy tumors before they destroy lives,” he said. Shamir emphasized the importance of introducing ProSense® to thousands of U.S. breast imaging professionals, particularly as the company anticipates potential regulatory approval for breast cancer treatment in the United States.